Neurocrine Biosciences, Voyager Therapeutics Announce Treatment with VY-AADC Improved Good ON Time (ON Time Without Troublesome Dyskinesia) by 1.7 Hours and Reduced OFF Time by 2.2 Hours at 12 Months in Patients with Parkinson's Disease
Charles Gross